Squamous cell carcinoma in dogs: treatment, prognosis and clinical trials

Dogs · USA & Canada

Understanding squamous cell carcinoma

Squamous cell carcinoma is a cancer of surface-lining cells and can arise in the skin, mouth, nasal cavity and other sites. Its behavior varies greatly by location, so a small cutaneous SCC and an oral or nasal SCC should not be thought of as the same disease. Site, depth and stage guide what the diagnosis means.

What does the prognosis look like?

The outlook for squamous cell carcinoma depends heavily on where it starts. A small skin lesion may be curable with local treatment, while tumors in some oral, nasal or other sites can be much more invasive. Site, depth, stage and the ability to obtain local control are more useful than a generic SCC survival number.

What matters next

Start with the exact site and depth of the tumor. A small superficial skin SCC and a deeply invasive tumor in another location need very different plans. If it has already been removed, review the margins; if it is still present, plan local treatment around the amount of tissue involved.

Where are you now?

The SCC is oral or nasal

Use site-specific guidance rather than a generic SCC prognosis. Oral and nasal tumors have different local anatomy, staging needs, and treatment options from a small cutaneous SCC.

The lesion was already removed

Review the exact primary site, depth, subtype, and measured margins. Incomplete margins may justify additional local treatment depending on anatomy and expected behavior.

It is extensive, recurrent, or metastatic

Separate the local-control problem from the systemic one. Treatment that improves function or comfort at the primary site can still be worthwhile even when distant disease is present.

If you are waiting for oncology

Use the waiting period to establish the exact primary site and local extent because SCC behavior varies sharply by location. A small cutaneous lesion should not trigger the same plan as oral, nasal or deeply invasive disease.

Questions to ask your oncologist

What is the exact primary site and subtype of this SCC?
Is this mainly a local-control problem, or is metastatic staging important here?
If margins are incomplete, is more local treatment recommended now rather than waiting for regrowth?

How the diagnosis may appear in the record

Squamous cell carcinoma is site dependent. Keep the precise skin, nasal, digital, oral, tonsillar, or other primary site with the pathology report. Depth, invasion into bone or other structures, differentiation when reported, measured margins, and lymph-node findings can change the plan.

Changes to watch for at home

Report persistent ulceration, bleeding, pain, growth, or loss of function at the primary site. Urgency depends on anatomy: breathing difficulty, inability to eat, uncontrolled bleeding, or rapidly worsening pain should not wait for a routine visit.

How it is usually treated

Treatment is primarily local and depends on site. Surgery, radiation and other local approaches can all be appropriate. Small superficial skin lesions may have several curative options, while deeper or anatomically difficult tumors may need combined local treatment. Systemic treatment is reserved for selected advanced cases.

What can affect treatment choices

Where the SCC starts, how deep it is, whether it invades nearby structures, margin status after surgery and whether it has spread determine whether this is mainly a local problem or needs a broader plan.

Tests that may matter

Biopsy and site-appropriate imaging are more useful than a generic cancer panel. Imaging is most helpful when the tumor is large, deep, near bone or in an anatomically difficult location. Regional lymph-node assessment is considered for higher-risk sites.

Treatment options available now

5 options currently in our catalog.

Check eligibility

Evaluation of TLR agonist Z-007 in dogs with cancer

Cummings School of Veterinary Medicine, Tufts University · USA

Location

Henry and Lois Foster Hospital for Small Animals, 200 Westboro Rd, North Grafton, MA 01536

Study details

Recruiting

What is being offered: Dog study of IV or intratumoral Z-007 for solid tumors including carcinomas, sarcomas and melanoma. Public criteria include a generally 2–7 cm repeat-biopsy-accessible tumor plus medical/laboratory requirements; no prior immunotherapy or autoimmune disease. Investigator prescreening required.

Who may qualify: Confirmed cancer diagnosis required; Min weight kg: 7; Measurable

May not qualify if: Prior immunotherapy

Costs / coverage: 🟡 Partially funded. Z-007 treatment through Day 63 and treatment of Z-007/biopsy-related side effects are covered; other owner costs should be confirmed with Tufts.

Contact: clinicaltrials@tufts.edu

Official study / enrollment information →

Palbociclib for selected progressive canine solid tumors

Auburn University College of Veterinary Medicine · USA

Location

Bailey Small Animal Teaching Hospital, 1220 Wire Rd, Auburn, AL 36849

Study details

Actively recruiting — confirmed on the institution’s current clinical-trials page

What is being offered: Dose-finding oral palbociclib treatment study for measurable progressive mammary carcinoma, SCC, histiocytic sarcoma, AGASACA or melanoma; prior cancer treatment is allowed if disease is progressing.

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Measurable; Progressive

Costs / coverage: After owner-paid initial exam/screening, up to two months of trial treatment including biopsy, rechecks, bloodwork and chemotherapy are funded.

Contact: Auburn Oncology Service — (334) 844-4690; onco@auburn.edu

Official study / enrollment information →

Intratumoral long-acting carboplatin for canine superficial squamous cell carcinoma

Bridge Animal Referral Center · USA

Location

Bridge Animal Referral Center, 8401 Main St, Edmonds, WA 98026, Edmonds, WA

Study details

Active enrollment at BARC for non-metastatic superficial squamous cell carcinoma

What is being offered: Intratumoral injection of a newly formulated lower-dose carboplatin designed for long-acting local activity.

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Measurable; Min tumor cm: 1; No metastasis

May not qualify if: Prior chemo; Prior immunotherapy; Prior local radiation

Costs / coverage: Fully funded: BARC states that study treatments and associated procedures have no cost to the owner.

Contact: Bridge Animal Referral Center, Edmonds — 425-697-2272

Official study / enrollment information →

Compassionate-Use Protocol for Advanced Non-Resectable Tumors

UT Southwestern Veterinary Research and Oncology Clinic · USA

Location

Veterinary Research and Oncology Clinic, 5801 Forest Park Rd, Dallas, TX 75235

Study details

Current

What is being offered: Investigational therapy, chemotherapy, immunotherapy and combination approaches under a prospective compassionate-use protocol

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Min weight kg exclusive: 2.5; min expected survival weeks: 3 weeks; Adequate organ function

May not qualify if: Severe systemic disease

Costs / coverage: ⚪ Owner-paid. The protocol brochure states that owners fully pay for the study, although possible subsidies may be available.

Contact: Paige Neumann, Research Study Coordinator — 214-645-6221; VROC@UTSouthwestern.edu

Official study / enrollment information →

Single-fraction SABR for progressive canine lung metastases

Tufts Cummings School of Veterinary Medicine · USA

Location

Henry and Lois Foster Hospital for Small Animals, 200 Westboro Rd, North Grafton, MA 01536

Study details

Recruiting

What is being offered: Single highly focused radiation dose for dogs with 2–10 progressive pulmonary metastatic nodules. The primary tumor, regional nodes and any non-pulmonary metastases must already be controlled; progression must be documented over 6–8 weeks, and all progressive lung lesions at least 5 mm must be safely treatable. Prior systemic therapy is allowed; cytotoxic chemotherapy pauses around SABR, while tolerated targeted therapy or immunotherapy may continue with radiation-oncologist approval. Tufts prescreening is required.

Who may qualify: Confirmed cancer diagnosis required; Active tumor required; Metastatic; Measurable lung metastases; Planned radiation

Costs / coverage: 🟡 Partially funded. The study covers SABR, the one-month follow-up, adverse-event rechecks related to lung toxicity, and up to $860 toward the 2–3-month CT visit. Owners pay pre-enrollment bloodwork, chest imaging, treatment-planning CT, and diagnostic confirmation.

Contact: Tufts Clinical Trials Office — clinicaltrials@tufts.edu; owner and referring-veterinarian prescreening questionnaires on the official page

Official study / enrollment information →